3-Hydroxyisobutyrate dehydrogenase (HIBADH) deficiency-A novel disorder of valine metabolism

Authors

Meyer M¹, Hollenbeck JC², Reunert J¹, Seelhöfer A¹, Rust S¹, Fobker M³, Biskup S⁴, Och U¹, Linden M⁵, Sass JO², Marquardt T¹

Department of General Pediatrics, University Hospital, Münster, Germany.
Bonn-Rhein-Sieg University of Applied Sciences, Department of Natural Sciences & Institute for Functional Gene Analytics (IFGA), RG Inborn Errors of Metabolism, Rheinbach, Germany.
Center for Laboratory Medicine, University Hospital, Münster, Germany.
CeGaT GmbH und Praxis für Humangenetik Tübingen, Tübingen, Germany.
private address.

Abstract

3-Hydroxyisobutyric acid (3HiB) is an intermediate in the degradation of the branched-chain amino acid valine. Disorders in valine degradation can lead to 3HiB accumulation and its excretion in the urine. This article describes the first two patients with a new metabolic disorder, 3-hydroxyisobutyrate dehydrogenase (HIBADH) deficiency, its phenotype and its treatment with a low-valine diet. The detected mutation in the HIBADH gene leads to nonsense-mediated mRNA decay of the mutant allele and to a complete loss-of-function of the enzyme. Under strict adherence to a low-valine diet a rapid decrease of 3HiB excretion in the urine was observed. Due to limited patient numbers and intrafamilial differences in phenotype with one affected and one unaffected individual, the clinical phenotype of HIBADH deficiency needs further evaluation.

Keywords: 3-hydroxyisobutyrate dehydrogenase; 3-hydroxyisobutyrate dehydrogenase deficiency; 3-hydroxyisobutyric aciduria; HIBADH; HIBADH deficiency; branched-chain amino acids; valine degradation.

References

View our Panel for Metabolic Diseases incl. Mitochondriopathies

View our publications

View this paper on NCBI